DISCOVERY AND DEVELOPMENTAL THERAPEUTICS PROGRAM

发现和开发治疗计划

• 批准号: 8512132
• 负责人: HAIAN FU
• 金额: $ 2.42万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-01 至 2017-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8512132
• 关键词: Accounting; Anti-Inflammatory Agents; Anti-inflammatory; Antineoplastic Agents; Biological; Biological Factors; Biological Markers; Biology; CXCR4 gene; Cancer Center Support Grant; Cancer Immunology Science; Cancer Patient; Cells; Cessation of life; Chemicals; Clinic; Clinical; Clinical Trials; Collaborations; Colorectal Cancer; Complement; Curcumin; Detection; Development; Developmental Therapeutics Program; Diagnostic; Direct Costs; Environment; Evaluation; Fostering; Funding; Funding Agency; Gene Expression Profile; Goals; Grant; Head and Neck Cancer; Heat-Shock Proteins 90; Human; Image; Imaging technology; Immune; Immune response; Institutes; Instruction; Lead; Leadership; Life Cycle Stages; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of lung; Mission; Modality; Molecular; Molecular Target; Monitor; Oncogenic; Paper; Pathway interactions; Patients; Peer Review; Pharmacologic Substance; Phase; Positron-Emission Tomography; Property; Public Health Schools; Publications; Publishing; Radiation; Recombinants; Recruitment Activity; Regimen; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Science; Scientific Advances and Accomplishments; Side; Signaling Pathway Gene; Survival Rate; Technology; Testing; Therapeutic; Therapeutic Agents; Therapeutic Intervention; Translating; Translations; Universities; Work; analog; base; cancer diagnosis; cancer genomics; cancer therapy; college; honokiol; improved; in vivo; inhibitor/antagonist; innovation; mTOR Inhibitor; medical schools; meetings; member; molecular imaging; nanoparticle; novel; novel therapeutics; operation; polypeptide; programs; research clinical testing; response; small molecule; theranostics; therapeutic target; tumor

PROJECT SUMMARY (See instructions): Discovery and Developmental Therapeutics (DDT) Program is the primary driver of discovery and evaluation of novel therapeutic options for patients with cancer at the Winship Cancer Institute. The DDT Program has developed and recruited expertise focused on four specific interconnected goals: 1) to identify small molecule cancer therapeutics; 2) to translate discoveries in cancer immunology into enhanced therapies; 3) to develop innovative in vivo imaging technologies; and 4) to accelerate targeted therapeutics into clinical trials. DDT Program members pursue these goals In the lab and in clinic, providing numerous opportunities for dynamic collaboration both intra- and inter-programmatically. DDT members published 505 cancer-related publications in the current project period and demonstrated that they are active as well as interactive. Specifically, intra-programmatic publications account for 23% and inter-programmatic publications account for 25% of their total cancer-relevant publications. The DDT Program has met significant milestones in pursuing its goals by capitalizing on its members' strengths and the opportunities available to them. DDT's 52 core members represent 14 departments across Emory University, including the School of Medicine, the School of Public Health and Emory College. DDT members currently have $34,792,000 in research grant funding (annual direct costs), of which $24,711,747 is peer-reviewed and $12,405,796 is NCI funded. Scientific advances are made possible by access to outstanding shared resources, the opportunity to compete for various funding sources, and the provision of matching funds for large research grants. These opportunities, combined with capable leadership, will continue to enable the DDT Program to translate technologic advances into therapeutic options for patients with cancer.

项目总结（见说明）： 发现和发展治疗（DDT）计划是Winship癌症研究所发现和评估癌症患者新治疗方案的主要驱动力。DDT计划开发和招募了专注于四个具体相互关联的目标的专业知识：1）确定小分子癌症疗法; 2）将癌症免疫学的发现转化为增强疗法; 3）开发创新的体内成像技术;以及4）加速靶向治疗进入临床试验。DDT计划成员在实验室和临床上追求这些目标，提供了许多 方案内和方案间的动态协作机会。滴滴涕成员在本项目期间出版了505份与癌症有关的出版物，表明这些出版物既积极又具有互动性。具体而言，计划内出版物占癌症相关出版物总数的23%，计划间出版物占25%。 滴滴涕方案通过利用其成员的优势和可利用的机会，在实现其目标方面取得了重要的里程碑。DDT的52名核心成员代表埃默里大学的14个系，包括医学院、公共卫生学院和埃默里学院。 滴滴涕成员目前有34，792，000美元的研究赠款资金（年度直接费用），其中24，711，747美元是同行评审资金，12，405，796美元是国家癌症研究所资金。 科学进步是通过获得优秀的共享资源，有机会竞争各种资金来源，以及为大型研究赠款提供匹配资金而实现的。这些机会，加上有能力的领导，将继续使滴滴涕计划将技术进步转化为癌症患者的治疗选择。